NewTimeSpace News: Hong Shing Cheong Resources issued a supplementary announcement on June 16 to provide further biographical information regarding Huang Zhenguo, who was previously appointed as Independent Non-executive Director.
NewTimeSpace News: Hong Kong Credit Corporation issued a positive profit alert on June 16, forecasting that profit attributable to shareholders for the year ended March 31, 2026 will increase by 40% to 60% compared with the previous year.
NewTimeSpace News: MINIEYE Innovation announced on June 16 that the Group has recently signed an autonomous logistics vehicle procurement agreement with an independent third-party enterprise in Wuxi. The counterparty will purchase a total of 1,000 autonomous logistics vehicles together with supporting software systems.
NewTimeSpace News: Baixin International disclosed in an announcement on June 16 that Ma Qinghai has resigned from his positions as Executive Director and Chief Executive Officer to devote more energy to other business engagements.
NewTimeSpace News: Regent Pacific Group announced in an announcement dated June 16 that the New Drug Application for its proprietary Senstend™ has been approved by the National Medical Products Administration, with a four-year data protection period attached.
NewTimeSpace News: Dongjiang Environment announced on June 16 that its controlled subsidiary Mianyang Dongjiang Environmental Technology Co., Ltd. remains unable to repay its loan. Pursuant to the guarantee contract, the Company will perform the indemnification obligation of approximately RMB1.1983 million to Postal Savings Bank of China.
NewTimeSpace News: CSPC Pharmaceutical Group announced on June 16 that the New Drug Application (NDA) for its self-developed Valsartan Levoamlodipine Maleate Tablets (Tablet SYH9056) has been accepted by the National Medical Products Administration.
NewTimeSpace News: Lisi Group Holdings released a profit forecast on June 16, expecting net profit of no less than RMB115 million for the year ended March 31, 2026.
NewTimeSpace News: Bank of Qingdao announced on June 16 that its employee representative congress convened on June 16, 2026, and elected Liu Xiaoshu as employee director of the 9th Board of Directors.
NewTimeSpace News: Tak Ngan Construction released a profit warning on June 16, forecasting a net loss of no more than HK$35 million for the year ended March 31, 2026.
NewTimeSpace News: Caocao Mobility announced in an announcement dated June 16 that Liu Sensen has resigned as Chief Financial Officer due to personal health reasons, effective June 22, 2026. Yuan Peng has been appointed Vice President and Chief Financial Officer, taking office on the same date.
NewTimeSpace News: Shenbao Department Store issued a supplementary announcement on June 16 regarding follow-up arrangements for the deferred consultancy fee agreement previously rejected by independent shareholders. The Company will not initiate legal action against Shen Runfeng for the time being, and will recover overdue consultancy fees via continuous debt collection, financial condition monitoring and other measures.
NewTimeSpace News: China Suntien Green Energy announced on June 16 that Guofu Fund, an indirect non-wholly-owned subsidiary of controlling shareholder Hebei Construction & Investment Group, purchased a total of 3.01 million H shares on June 16 with a consideration of approximately RMB9.0178 million.
NewTimeSpace News: Qiniu Intelligence disclosed in a supplementary announcement dated June 16 that cloud service fees charged to AlipayHK are benchmarked against quotations from no less than three independent third parties, with a profit margin of 5% to 25% marked up on costs, consistent with terms offered to independent third-party customers.
NewTimeSpace News: Bank of China Limited (03988.HK) announced on June 16 that it has completed the issuance of RMB50 billion Tier 2 capital bonds carrying a coupon rate of 1.93%. The bonds have a 10-year tenor with a call right exercisable by the issuer at the end of Year 5, and the proceeds will be used to supplement the Bank’s Tier 2 capital.
NewTimeSpace News: Shanghai Henlius Biotech Co., Ltd. (02696.HK) announced that the Phase 2 clinical trial of HLX43 for Injection, a PD-L1-targeted antibody-drug conjugate (ADC), in combination with Hansizhu® (serplulimab injection) for neoadjuvant therapy of non-small cell lung cancer (NSCLC), has obtained approval from the relevant Human Research Ethics Committee (HREC) of Australia and completed Clinical Trial Notification (CTN) filing with the Therapeutic Goods Administration (TGA). Previously, key subgroup data of HLX43 in NSCLC were presented as a rapid oral abstract at the 2026 ASCO Annual Meeting.
